PATH | VRL
Menu

Safety and Immunogenicity of a Parenteral P2-VP8-P[8] Subunit Rotavirus Vaccine in Toddlers and Infants in South Africa: A Randomised, Double-Blind, Placebo-Controlled Trial

Low-income countries in Africa and Asia have the highest burden of rotavirus disease, but live oral rotavirus vaccines have shown reduced efficacy in these countries compared with high-income countries. This article, published in the Lancet Infectious Diseases, assessed the safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine at different doses in infants and toddlers in South Africa. The authors found the parenteral monovalent vaccine candidate to be well tolerated and immunogenic in infants, providing a novel approach to vaccination against rotavirus. The results of this study support further development and testing, and a Phase 1/2 trial of a trivalent P2-VP8 (P[4], P[6], and P[8]) subunit vaccine candidate is underway in South Africa.

Author: Groome MJ, Koen A, Fix A, et al.

Published: 2017

» Visit web page (English)

(Located at www.thelancet.com)

CitationGroome MJ, Koen A, Fix A, et al. Safety and Immunogenicity of a Parenteral P2-VP8-P[8] Subunit Rotavirus Vaccine in Toddlers and Infants in South Africa: A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Infectious Diseases. 2017;Early Online Publication.

Resource types: Peer-reviewed journal

Diseases/vaccines: Rotavirus

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Africa